Phospho-ERK is a biomarker of response to a synthetic lethal drug combination of sorafenib and MEK inhibition in liver cancer

[Display omitted] •ERK2 inhibition was identified as an enhancer of the response to sorafenib in HCC.•Selumetinib increases the response of sorafenib in HCC cell lines with high p-ERK.•The synthetic lethal effect is derived from synergistic inhibition of ERK kinase.•The combination therapy is most l...

Celý popis

Uložené v:

Podrobná bibliografia
Vydané v:	Journal of hepatology Ročník 69; číslo 5; s. 1057 - 1065
Hlavní autori:	Wang, Cun, Jin, Haojie, Gao, Dongmei, Lieftink, Cor, Evers, Bastiaan, Jin, Guangzhi, Xue, Zheng, Wang, Liqin, Beijersbergen, Roderick L., Qin, Wenxin, Bernards, René
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	Netherlands Elsevier B.V 01.11.2018 Elsevier Science Ltd
Predmet:	Apoptosis Biomarkers Caspase Caspase-3 Clinical outcomes CRISPR CRISPR screen Drug therapy Extracellular signal-regulated kinase Hepatocellular carcinoma Hepatocytes Inhibitor drugs Lethality Liver cancer MAPK1 MEK inhibitors Patients Sorafenib Tumor cell lines Tumors Xenografts Hepatocellular carcinoma CRISPR screen MAPK1 Sorafenib
ISSN:	0168-8278, 1600-0641, 1600-0641
On-line prístup:	Získať plný text
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!

Buďte prvý, kto okomentuje tento záznam!